Clinical Trials

NOW RECRUITING: Phase 2 study of LN-144 followed by IL-2 in the treatment of refractory metastatic melanoma

Lion is conducting a Phase 2 clinical trial to assess the safety, efficacy and feasibility of an adoptive cell therapy based on autologous TIL (LN-144), followed by IL-2, in the treatment of patients with refractory metastatic melanoma. The multi-center, single-arm trial is now recruiting patients at various sites in the US.

PHYSICIANS: To learn more about the trial on ClinicalTrials.gov, including eligibility criteria, locations and contacts, please click here. (Identifier: NCT02360579).

About LN-144

Manufactured with TIL derived from the patient’s own tumor, LN-144 is based on adoptive cell therapy regimen that was developed at the National Cancer Institute (NCI) and is currently in use at leading US cancer centers. Recent data from a Phase 2 trial in heavily pre-treated patients with metastatic melanoma at NCI confirmed that TIL treatment was associated with high, durable objective response rates (ORR), including in patients who were refractory to checkpoint inhibitors. Complete responses (total elimination of tumors) have been observed in 24% of patients, some of whom have been free of disease for more than ten years.

For a summary of the latest NCI trial data, please click here.
To view a list of publications and presentations, click here.

PATIENTS: Learn more

If you have been diagnosed with metastatic melanoma, have previously undergone at least one systemic treatment, and are interested in participating in this trial, please talk to your doctor. If you have other questions or would like more information on this trial from our contract research organization, Vector Oncology, please sign up below. We will not share your name or contact information with any other outside parties — your privacy is important to us.